S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
OTCMKTS:HPPI

HedgePath Pharmaceuticals Stock Forecast, Price & News

$0.13
+0.03 (+29.84%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.13
▼
$0.13
50-Day Range
$0.09
▼
$0.16
52-Week Range
$0.04
▼
$0.32
Volume
3,021 shs
Average Volume
19,283 shs
Market Capitalization
$48.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.16
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive HPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for HedgePath Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Headlines

HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
August 19, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
May 29, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
May 6, 2019 |  finance.yahoo.com
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals
April 15, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018
March 7, 2019 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HPPI
Previous Symbol
CUSIP
N/A
CIK
1042418
Web
www.hedgepathpharma.com
Phone
813-509-2417
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-13.06

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-4.55 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-246.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.76
Quick Ratio
6.76

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
370,446,000
Free Float
N/A
Market Cap
$48.36 million
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












HedgePath Pharmaceuticals (OTCMKTS:HPPI) Frequently Asked Questions

How has HedgePath Pharmaceuticals' stock price been impacted by Coronavirus?

HedgePath Pharmaceuticals' stock was trading at $0.0799 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HPPI shares have increased by 63.4% and is now trading at $0.1306.
View which stocks have been most impacted by COVID-19.

Who are HedgePath Pharmaceuticals' key executives?

HedgePath Pharmaceuticals' management team includes the following people:
  • Mr. Nicholas Jon Virca, Pres & CEO (Age 73)
  • Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50)

What other stocks do shareholders of HedgePath Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HedgePath Pharmaceuticals investors own include TransAtlantic Petroleum (TAT), Eaton (ETN), Diamond Offshore Drilling (DO), Correvio Pharma (CORV), Clorox (CLX), CIT Group (CIT), Bank of Montreal (BMO), Blue Sphere (BLSP), BJ's Wholesale Club (BJ) and Alimentation Couche-Tard (ATD.B).

What is HedgePath Pharmaceuticals' stock symbol?

HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HPPI."

How do I buy shares of HedgePath Pharmaceuticals?

Shares of HPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HedgePath Pharmaceuticals' stock price today?

One share of HPPI stock can currently be purchased for approximately $0.13.

How much money does HedgePath Pharmaceuticals make?

HedgePath Pharmaceuticals has a market capitalization of $48.36 million.

How many employees does HedgePath Pharmaceuticals have?

HedgePath Pharmaceuticals employs 2 workers across the globe.

What is HedgePath Pharmaceuticals' official website?

The official website for HedgePath Pharmaceuticals is www.hedgepathpharma.com.

Where are HedgePath Pharmaceuticals' headquarters?

HedgePath Pharmaceuticals is headquartered at 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609.

How can I contact HedgePath Pharmaceuticals?

HedgePath Pharmaceuticals' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at 813-509-2417 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.